Form 8-K - Current report:
SEC Accession No. 0001023024-24-000093
Filing Date
2024-09-20
Accepted
2024-09-20 16:03:19
Documents
16
Period of Report
2024-09-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ani-20240916.htm   iXBRL 8-K 58212
2 EX-10.1 exhibit101contingentvaluer.htm EX-10.1 185169
3 EX-23.1 exhibit231consentofgrantth.htm EX-23.1 2391
4 EX-99.3 exhibit993unauditedproform.htm EX-99.3 384139
  Complete submission text file 0001023024-24-000093.txt   823006

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ani-20240916.xsd EX-101.SCH 1874
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ani-20240916_lab.xml EX-101.LAB 21629
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ani-20240916_pre.xml EX-101.PRE 12491
18 EXTRACTED XBRL INSTANCE DOCUMENT ani-20240916_htm.xml XML 2690
Mailing Address 210 MAIN STREET WEST BAUDETTE MN 56623
Business Address 210 MAIN STREET WEST BAUDETTE MN 56623 2186343500
ANI PHARMACEUTICALS INC (Filer) CIK: 0001023024 (see all company filings)

EIN.: 582301143 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31812 | Film No.: 241313382
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)